COMMUNIQUÉS West-GlobeNewswire

GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
13/01/2025
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 13 janvier 2025 – GENFIT (Nasdaq et Euronext: GNFT) , société biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie [...]
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
13/01/2025
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 13, 2025 – GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients [...]
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
13/01/2025
AMF Regulated Information Châtillon, France, January 13, 2025 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), [...]
Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF
13/01/2025
Informations Réglementées Châtillon, France, le 13 janvier 2025 Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq : DBVT), [...]
OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2024 and Issues 2025 Financial Guidance
13/01/2025
Achieves all-time high full year 2024 Revenue of $205 million representing growth of 38% Year-Over-Year Initiates guidance for record adjusted EBITDA in 2025 WARSAW, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- [...]
Micron Biomedical Wins $2 Million BARDA Competition for Its Collaboration with Zipcode Bio to Develop mRNA-Based Broad Protecting Flu Vaccine Without Needles
13/01/2025
U.S. Department of Health and Human Services (HHS) office, BARDA, awards Micron $2 million to continue its work on broadly-protecting avian and seasonal flu vaccines SAN FRANCISCO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- [...]
Merus et Biohaven annoncent une collaboration pour co-développer trois nouveaux programmes de CAM bispécifiques
13/01/2025
NEW HAVEN, Connecticut, et UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 13 janv. 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE : BHVN) et Merus N.V. (Nasdaq : MRUS) ont annoncé ce jour une collaboration de recherche et [...]
Correction: GUERBET : Financial agenda for 2025
13/01/2025
Financial agenda for 2025 Villepinte, 13 janvier 2025 : Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2025. Publications [...]
Correction: GUERBET : Calendrier financier de l'exercice 2025
13/01/2025
Calendrier financier de l’exercice 2025 Villepinte, le 13 janvier 2025 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, publie son calendrier financier [...]
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer
13/01/2025
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer NANTES, France, January 13, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , today announced the [...]
OSE Immunotherapeutics annonce la nomination du Dr. Sonya Montgomery au poste de Chief Development Officer
13/01/2025
OSE Immunotherapeutics annonce la nomination du Dr. Sonya Montgomery au poste de Chief Development Officer Nantes, France, le 13 janvier 2025, 18 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) [...]
Press release: Transparency Notification from Shareholders
13/01/2025
Transparency Notification from Shareholders Ghent, Belgium – 13 January 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer in the treatment of fluid overload in [...]
BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones
13/01/2025
- Remarkable early Attruby demand: 430 scripts written by 248 unique HCPs since FDA approval with broad uptake across academic centers and community centers in all patient types - Fully enrolled three major market Phase [...]
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
13/01/2025
Company announcement – No. 1 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, January [...]
ProMIS Neurosciences Issues Letter to Shareholders
13/01/2025
CAMBRIDGE, Massachusetts, Jan. 13, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (ProMIS), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics [...]
Baylor Genetics to Integrate with Epic Aura to Enhance Efficiency and Deliver Genetic Testing Results to Hospitals and Health Systems
13/01/2025
The company will be the first to integrate whole genome sequencing (WGS) into Epic's Aura platform, further advancing access to genetic insights for patients and providers in the neonatal and pediatric intensive care [...]
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola
13/01/2025
This option is part of Emergent’s existing 10-year contract with BARDA for advanced development and procurement of Ebanga™, with a maximum value of $704 million Program progress and performance triggers $16.7 million [...]
Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones
13/01/2025
Continued Focus on Driving Advancement of TN-201 and TN-401 Gene Therapies for Cardiomyopathies Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated [...]
NAYA Biosciences Announces Pricing of $9.5 Million Public Offering
13/01/2025
SARASOTA, Fla. and MIAMI, Jan. 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune [...]

Pages